BrainChip Holdings Ltd (ASX: BRN) has released several significant announcements in November 2025, primarily focusing on a capital raising initiative and a strategic partnership. The company announced a A$35 million institutional placement and a share purchase plan (SPP) to raise up to an additional A$2 million [1]. This capital raise, fully underwritten for the placement, aims to accelerate the commercialization of its Akida neuromorphic technology platform, develop next-generation edge AI products, support research and development for its Generative AI platform, and advance next-generation chip architecture design [1]. The placement involved the issue of 200 million shares at A$0.175 per share, representing a 10.3% discount to the last closing price on November 5, 2025 [1] [3]. The SPP, also at A$0.175 per share, is open to eligible shareholders in Australia and New Zealand, closing on November 28, 2025 [1].

According to www.iAsk.Ai - Ask AI:

BrainChip also requested a trading halt on the Australian Securities Exchange (ASX) on November 8, 2025, in anticipation of the capital raising announcement [6]. Furthermore, the company announced a strategic partnership with Blue Ridge Envisioneering (BRE), a Parsons company (NYSE: PSN) [5]. This agreement focuses on accelerating edge AI defense systems by integrating BrainChip’s Akida™ neuromorphic processors into Parsons' mission-ready edge-AI platforms, aiming to enhance adaptive performance in constrained and dynamic defense environments without reliance on cloud connectivity [5].